The FDA has approved the SetPoint System, a neuroimmune modulation device, for the treatment of adults with moderately to severely active rheumatoid arthritis.

The incidence of new-onset IA was higher after Lyme disease diagnosis vs influenza, especially during the first year postinfection.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

The addition of medial opening wedge high tibial osteotomy to nonsurgical management reduced loss of articular cartilage.

Rituximab was no better than glucocorticoids alone for inducing remission in patients with eosinophilic granulomatosis with polyangiitis.

A US District Judge blocked a law that stopped Medicaid payments to many Planned Parenthood clinics nationwide.

Structured 2-year lifestyle interventions were associated with significantly better cognitive trajectory in older adults.

Among patients with PsA, MetS was independently associated with a D2T phenotype, even when accounting for fibromyalgia and disease activity.

The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.

Obinutuzumab, a B-cell depleting therapy, is being explored for reducing lupus nephritis risks, such as flare.

The Mediterranean, AHEI, and DASH dietary patterns were linked to reduced risk of type 2 diabetes across ethnic groups.